Randomized clinical trial on the safety and the efficacy of Tegaderm for the prevention of hypernatremic dehydratation in preterm infants

Randomized clinical trial on the safety and the efficacy of Tegaderm for the prevention of hypernatremic dehydratation in preterm infants - Tegaderm use in preterm infants

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010515

Enrollment

160

Registered

2013-09-25

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypernatremic dehydratation

Interventions

application of Tegaderm whitin 24 hour of life no treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inborn newborn infants with gestational age < 30 weeks

Exclusion criteria

Exclusion criteria: major congenital malformations, chromosomal abnormalities, congenital infections, acute renal insufficiency

Design outcomes

Primary

Measure	Time frame
Incidence of hypernatremia (plasma sodium > 145 mEq/L)	—

Secondary

Measure	Time frame
Maximum weight loss, birth weight regain, hypotermia, hypertermia, intraventricular haemorrhage, sepsis, patent ductus arteriosus, systemic hypotension, bronchopulmonary dysplasia, necrotizing enterocolitis, retinopathy of prematurity, lenght of stay	—

Countries

Europe

Contacts

Public ContactSimonetta Costa

Catholic University of Sacred Heart Division of Neonatology

simocosta@yahoo.it+390630154357

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026